ArticleIndian journal of psychiatry2026
Specific psychiatric symptoms during cannabis use and their relation to psychotic disorders.
Article in Indian journal of psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objectives: Cannabis use is an increasing phenomenon worldwide and represents a controversial issue, as it has direct implications in the development of psychosis. There are no widely accepted tools of evaluating the risk for users and therefore no prevention strategies. As psychosis and schizophrenia are two major psychiatric disorders, developing a screening tool is of great need. The current study evaluates the feasibility of the cannabis experience questionnaire 6 (CEQ-6) questionnaire as a screening tool for cannabis users that are at high risk of developing psychosis or schizophrenia. Methods: In this study, 400 patients were selected from the Drug Addiction Department of the Cluj County Emergency Clinical Hospital. The cohort was divided into three groups: patients with cannabis use, but with no current or previous history of cannabis-induced psychotic disorders; patients with current or previous history of cannabis-induced psychotic disorders, and patients diagnosed with schizophrenia having a positive history of cannabis-induced psychotic disorders. Results: There are several items of the CEQ-6 questionnaire that can be linked with the risk of developing psychosis and schizophrenia-auditory hallucinations during use, feeling disinhibited after use, and the sensation of understanding the world better during use. Furthermore, some items can be used for assessing the risk of schizophrenia in patients with cannabis-induced psychosis. Conclusions: The study shows a possibility of utilizing CEQ-6 as a screening tool for identifying users at high-risk of psychosis. This is an important step toward prevention in the general population as the scale can be applied outside the psychiatric setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.